Glenmark Q4 PAT seen up 11% at Rs 127 cr

Drug manufacturer Glenmark Pharma is expected to report a growth of 11% year-on-year in its profit after tax of Rs 127 crore for the fourth quarter of FY12 (as per IFRS), according to CNBC-TV18.

Revenues are seen going up by 26% to Rs 1,000 crore from Rs 795 crore during the same period.
EBITDA is likely to be doubled at Rs 191 crore for the January-March quarter of 2012 as against Rs 89.3 crore in a year ago period.
Operating profit margin is seen improving at 19% versus 11.2%.
 
Year-on-year growth is likely to be led by US markets and Latin America/ROW + Europe. Indian business will be sluggish sequentially due to inventory rationalisation while margins will be boosted by forex gain.